JP5575651B2 - 新規のｄｈａ誘導体およびその医薬品としての用途 - Google Patents

新規のｄｈａ誘導体およびその医薬品としての用途 Download PDF

Info

Publication number
JP5575651B2
JP5575651B2 JP2010530588A JP2010530588A JP5575651B2 JP 5575651 B2 JP5575651 B2 JP 5575651B2 JP 2010530588 A JP2010530588 A JP 2010530588A JP 2010530588 A JP2010530588 A JP 2010530588A JP 5575651 B2 JP5575651 B2 JP 5575651B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
group
compound according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010530588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502113A5 (cg-RX-API-DMAC7.html
JP2011502113A (ja
Inventor
クリスティン ホルマイデ，アン
ホヴランド，ラグナー
Original Assignee
プロノヴァ バイオファーマ ノルゲ アーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロノヴァ バイオファーマ ノルゲ アーエス filed Critical プロノヴァ バイオファーマ ノルゲ アーエス
Publication of JP2011502113A publication Critical patent/JP2011502113A/ja
Publication of JP2011502113A5 publication Critical patent/JP2011502113A5/ja
Application granted granted Critical
Publication of JP5575651B2 publication Critical patent/JP5575651B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/24—Preparation of carboxylic acid esters by reacting carboxylic acids or derivatives thereof with a carbon-to-oxygen ether bond, e.g. acetal, tetrahydrofuran
    • C07C67/26—Preparation of carboxylic acid esters by reacting carboxylic acids or derivatives thereof with a carbon-to-oxygen ether bond, e.g. acetal, tetrahydrofuran with an oxirane ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2010530588A 2007-10-31 2008-10-30 新規のｄｈａ誘導体およびその医薬品としての用途 Expired - Fee Related JP5575651B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US109707P 2007-10-31 2007-10-31
US61/001,097 2007-10-31
PCT/IB2008/003666 WO2009056983A1 (en) 2007-10-31 2008-10-30 New dha derivatives and their use as medicaments

Publications (3)

Publication Number Publication Date
JP2011502113A JP2011502113A (ja) 2011-01-20
JP2011502113A5 JP2011502113A5 (cg-RX-API-DMAC7.html) 2011-12-15
JP5575651B2 true JP5575651B2 (ja) 2014-08-20

Family

ID=40374914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010530588A Expired - Fee Related JP5575651B2 (ja) 2007-10-31 2008-10-30 新規のｄｈａ誘導体およびその医薬品としての用途

Country Status (5)

Country Link
US (1) US20100267828A1 (cg-RX-API-DMAC7.html)
EP (1) EP2217558A1 (cg-RX-API-DMAC7.html)
JP (1) JP5575651B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100100818A (cg-RX-API-DMAC7.html)
WO (1) WO2009056983A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2248798A1 (en) * 2009-05-08 2010-11-10 Pronova BioPharma Norge AS Novel lipid compounds
CN102459142B (zh) * 2009-05-08 2017-08-08 普罗诺瓦生物医药挪威公司 用于治疗与心血管、代谢和炎性疾病领域相关的疾病的多不饱和脂肪酸
SG10201509127YA (en) * 2010-11-05 2015-12-30 Pronova Biopharma Norge As Methods of treatment using lipid compounds
WO2013123290A1 (en) 2012-02-15 2013-08-22 Anida Pharma Inc. Methods of treating amyotrophic lateral sclerosis
ES2748562T3 (es) 2013-02-28 2020-03-17 Basf As Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y procedimientos de uso de la misma
CN107530306A (zh) 2015-04-28 2018-01-02 普罗诺瓦生物医药挪威公司 结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途
CN113214084A (zh) * 2015-11-23 2021-08-06 乐巢拓普有限公司 1,4-二烯体系的位点特异性同位素标记
IL275002B2 (en) 2017-12-06 2024-04-01 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
IL321252A (en) 2020-02-21 2025-08-01 Retrotope Inc Processes for isotopic alteration of polyunsaturated fatty acids and their derivatives

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2836628A (en) * 1955-10-17 1958-05-27 Monsanto Chemicals Unsaturated branched-chain alcohols and methods of preparing same
US4132719A (en) * 1978-04-20 1979-01-02 Mcneilab Inc. Dibromoalkylglycidic acid derivatives
US4264517A (en) * 1978-12-11 1981-04-28 G.D. Searle & Co. Alkylphenyl 5Z,8Z,11Z,14Z,17Z-eicosapentaenoates
US4647685A (en) * 1985-04-25 1987-03-03 Eli Lilly And Company 2-alkoxy-1-((2-trialkylaminoethoxy)phosphinyloxy)-alkenes and alkynes, hydroxy inner salts
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5422371A (en) * 1992-05-27 1995-06-06 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
JPH0692848A (ja) * 1992-09-11 1994-04-05 Sagami Chem Res Center 糖尿病治療用乳剤
JPH06192177A (ja) * 1992-10-27 1994-07-12 Sando Yakuhin Kk グリセリン誘導体並びにこれを含有する血小板凝集抑制剤および脂肪輸液剤
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
JP4530311B2 (ja) * 2000-07-13 2010-08-25 日本水産株式会社 リパーゼを用いたグリセライドの製造方法
JP2002180082A (ja) * 2000-12-11 2002-06-26 Maruha Corp 摂取物
US20040235948A1 (en) * 2003-03-05 2004-11-25 Solvay Pharmaceuticals Gmbh Treatment of diabetic patients with omega-3-fatty acids
KR101199599B1 (ko) * 2003-03-27 2012-11-12 산토리 홀딩스 가부시키가이샤 지질 개선제 및 지질 개선제를 함유하는 조성물
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
US20060183174A1 (en) * 2005-02-11 2006-08-17 Leong Ng Diagnosis
JP5337479B2 (ja) * 2005-05-04 2013-11-06 プロノヴァ・バイオファーマ・ノルゲ・アーエス 新規化合物
JP2010508262A (ja) * 2006-11-01 2010-03-18 プロノヴァ バイオファーマ ノルゲ アーエス 組成物
MX2009004336A (es) * 2006-11-01 2009-05-22 Pronova Biopharma Norge As Lipidos omega-3 alfa-sustituidos que son activadores o moduladores del receptor activado por proliferadores de peroxisoma (ppar).

Also Published As

Publication number Publication date
EP2217558A1 (en) 2010-08-18
KR20100100818A (ko) 2010-09-15
JP2011502113A (ja) 2011-01-20
US20100267828A1 (en) 2010-10-21
WO2009056983A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
JP5575651B2 (ja) 新規のｄｈａ誘導体およびその医薬品としての用途
AU2020205213B2 (en) Use of derivatives of polyunsaturated fatty acids as medicaments
RU2509071C2 (ru) Новые липидные соединения
JP5552313B2 (ja) 脂質化合物
EP2427415B1 (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
AU2006242914B2 (en) New DHA derivatives and their use as medicaments
JP3553966B2 (ja) 非−β−酸化可能脂肪酸類似体、治療用活性薬剤としてのその利用及びその調製方法
JP5552314B2 (ja) 新規脂質化合物
JP2010509204A (ja) 脂肪酸アルコール
KR20200016613A (ko) 새로운 ｄｈａ 유도체 및 약물로서 그들의 사용
RU2507193C2 (ru) Альфа-замещенные омега-3 липиды, которые являются активаторами или модуляторами рецептора, активируемого пролифераторами пероксисом (ppar)
WO2003004484A1 (en) Novel aliphatic compounds, synthesis method and method of using the same
HK1157742A1 (en) New dha derivatives and their use as medicaments

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131015

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140702

R150 Certificate of patent or registration of utility model

Ref document number: 5575651

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees